TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21810044
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 500 mg PLC
Study: 21810044
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1000 mg PLC
Study: 21810044
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 500 mg PLC twice a day over 7 days
Study: 21810044
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 1000 mg PLC twice a day over 7 days
Study: 19654097
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical management (proton pump inhibitors)
Study: 15599861
Drug: Concomitant radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant radiotherapy and chemotherapy (RT-CT) - 226 patients; 70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and 5-fluorouracil (5FU)
Study: 10669274
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia followed by an infusion of normal saline (Control)
Study: 10669274
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with continuous epidural infusion of 2% lidocaine (Group II)
Study: 10669274
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with K+M+B administered 10 min after 2% lidocaine injection and 30 min before skin incision (Group III)
Study: 1307517
Drug: Inhaled aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aerosol of platelet activating factor (PAF)
Study: 3834227
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro treatment with CUP membrane fragments
Study: 24324048
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of perindopril-indapamide (4/1.25 mg)
Study: 21148615
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m² i.v. every 21 days until disease progression)
Study: 17702126
Drug: Long-term peroral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term peroral anticoagulation treatment for 6 to 12 months
Study: 17702126
Drug: Three-month treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-month treatment period
Study: 10669897
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: four tablets at 0, 8, 24 and 48 h (320 mg artemether, 1,920 mg benflumetol)
Study: 10669897
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: two tablets at 0, 8, 24 and 48 h (160 mg artemether, 960 mg benflumetol)
Study: 10669897
Drug: Regimen C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C: four tablets at 0, 8 and 24 h (240 mg artemether, 1,440 mg benflumetol)
Study: 9534283
Drug: i.v. isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. isoproterenol infusion (low doses)
Study: 9534283
Drug: i.v. isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. isoproterenol infusion (higher doses)
Study: 1722935
Drug: barucainide (300-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: barucainide (300-400 mg/day)
Study: 6799558
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and insulin
Study: 6799558
Drug: Glucose, insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose, insulin and amino acids
Study: 24363760
Drug: TPN (Total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN (Total Parenteral Nutrition)
Study: 6799558
Drug: Energy supply
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy supply >120-130% of daily energy output
Study: 27052991
Drug: Lanconone® (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanconone® (1000 mg)
Study: 18833115
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with additional dosage of levodopa/DDC inhibitor
Study: 15684256
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) injections (40,000 UI/week subcutaneously until Ht of 40%)
Study: 15684256
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood donation (ABD) (RBC pack collected weekly as long as Ht was above 33%)
Study: 15114293
Drug: i.v. Dextran-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. Dextran-40 infusion (Group I, n = 48)
Study: 15114293
Drug: i.v. albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. albumin infusion (Group II, n = 48)
Study: 10798009
Drug: Sugar excretion
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar excretion measurement
Study: 7597269
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer
Study: 2035777
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms of fentanyl administered prophylactically by the epidural route
Study: 31721905
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% compound lidocaine cream (0.2 g/cm2)
Study: 31721905
Drug: Morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine group (10 mg tablet)
Study: 23429575
Drug: Combined optical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined optical and atropine treatment (COAT)
Study: 21829015
Drug: Heparin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 1,000 U/ml (group 2)
Study: 21829015
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 U/ml (group 1)
Study: 21829015
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (1,000 U/ml and 5,000 U/ml)
Study: 17728047
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration (50 mg)
Study: 15170922
Drug: Anakinra 75
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 75 mg/day
Study: 15170922
Drug: Anakinra 150
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 150 mg/day
Study: 1975426
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of pentamidine every two weeks
Study: 1975426
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of pentamidine every two weeks
Study: 1975426
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of pentamidine every four weeks
Study: 159510
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (40 microgram) administered as two puffs from a metered dose inhaler four times a day for one week (regular use)
Study: 159510
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ipratropium bromide (40 microgram) given 2.5 hours before the test
Study: 159510
Drug: Placebo (propellants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (propellants only) administered four times a day for one week (regular use)
Study: 11563899
Drug: Mesoglycan, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan, 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally, as an adjunct to compression therapy and topical wound care.
Study: 11563899
Drug: Placebo, as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, as an adjunct to compression therapy and topical wound care.
Study: 9758288
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice daily for 5 days with 200 mg trovafloxacin once daily from day 3-5
Study: 9758288
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 5 days with 200 mg trovafloxacin once daily from day 3-5
Study: 7823272
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of metronidazole gel
Study: 3245293
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (3 administrations of microgranules)
Study: 22743161
Drug: Persistent drug
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent drug users (used illicit drugs other than marijuana and/or nonmedical prescription drugs every year during the first four years)
Study: 22743161
Drug: Persistent drug
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent drug users and infrequent marijuana users
Study: 3022785
Drug: Interferon (topically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (topically applied in a gel)
Study: 29953567
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (commercially available denture adhesive cream)
Study: 24141036
Drug: Risedronate 150
Normalized name: risedronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 150 mg orally every month
Study: 21211262
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of high‐dose pirarubicin during perioperative period
Study: 1653142
Drug: Sumatriptan (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (100-300 mg oral)
Study: 1653142
Drug: Sumatriptan (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (4-8 mg subcutaneous)
Study: 6136437
Drug: Long-acting vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting vaginal pessary containing 3.0 mg 15-methyl-PGF2(α) methyl ester
Study: 6136437
Drug: Intraamniotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraamniotic administration of 2.5 mg 15-methyl-PGF2(α)
Study: 6136437
Drug: Long-acting vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting vaginal pessary complemented with intramuscular injections of 15-methyl-PGF2(α) (0.2-0.4 mg every third hour for up to 12 hours)
Study: 6136437
Drug: Intraamniotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraamniotic administration of 15-methyl-PGF2(α)
Study: 30247950
Drug: Mistletoe extracts
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extracts (Helixor A, Iscador M Spez) injected three times per week during 18 weeks of chemotherapy
Study: 16968813
Drug: Both Pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Pioglitazone and Metformin
Study: 15030987
Drug: 18 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18 months combination therapy with interferon (3MU tiw) and ribavirin (1000-1200 mg/day)
Study: 15030987
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months combination therapy with interferon and ribavirin
Study: 9661572
Drug: i.v. fluconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fluconazole 400 mg
Study: 9661572
Drug: oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral fluconazole 400 mg
Study: 4596632
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate administered for six weeks
Study: 31124381
Drug: Cholecalciferol tablet
Normalized name: Alendronate Sodium and Cholecalciferol Tablets
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol tablet 60,000 IU per week for 8 weeks
Study: 28867602
Drug: Secnidazole 2
Normalized name: secnidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole 2 g
Study: 21557440
Drug: Neutral protamine
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral protamine hagedorn insulin
Study: 16687897
Drug: Initial resuscitation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial resuscitation, appropriate antimicrobial treatment, selection of optimal control methods, properties of fluid therapy, use of vasopressors and inotropic therapy, proper corticosteroid administration, use of recombinant human activated protein C, glucose control
Study: 7961011
Drug: Total duration
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total duration of treatment < 55 days
Study: 7961011
Drug: Dose rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose rate
Study: 26683985
Drug: Parent education
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent education brochure plus a student curriculum on the four recommended vaccines
Study: 19731862
Drug: Itraconazole (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (administered to group A)
Study: 16353228
Drug: Sonographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographically guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Study: 16353228
Drug: Palpation-guided steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Study: 10911415
Drug: 10 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weeks of supervised physical therapy
Study: 8864313
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg racemic ketoprofen
Study: 8864313
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg racemic ketoprofen
Study: 1551350
Drug: Alginic acid-antacid
Normalized name: Alginic Acid
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginic acid-antacid (extra-strength Gaviscon)
Study: 1551350
Drug: Control antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control antacid (equal acid-neutralizing capacity)
Study: 30584459
Drug: Polyphenol-rich herbal
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich herbal congee (D2 group, 1500 mg/day)
Study: 30584459
Drug: Polyphenol-rich herbal
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich herbal congee (D1 group, 50 mg/day)
Study: 27662495
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for 10 minutes at GV 26, Ex-HN 3, bilateral LI 4, and ST 36
Study: 15950847
Drug: Intravenous hydroxyethyl
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydroxyethyl starch (HES) 6% 200,000/0.5, 500 mL
Study: 15950847
Drug: Electrolyte solution,
Normalized name: electrolyte solution,lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution, 500 mL
Study: 12390336
Drug: High-level TSH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-level TSH suppression (0.4-0.6 mIU/ml)
Study: 12390336
Drug: Low-level TSH
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level TSH suppression (< or = 0.01 mIU/ml)
Study: 10563539
Drug: Regular paper-filtered
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular paper-filtered coffee (280 ml)
Study: 10563539
Drug: Warm water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm water (280 ml)
Study: 26012232
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injected subcutaneous (GA)
Study: 26012232
Drug: Saline subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline subcutaneous & deep (GC)
Study: 19153001
Drug: Epirubicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (80 mg in 50 ml of saline) intravesically within 24 h of TUR
Study: 19153001
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after TUR
Study: 17578314
Drug: Ruyi Dingchuan
Normalized name: BENZALKONIUM CHLORIDE 0.148 g in 100 mL TOPICAL SPRAY [Jingchuang Chonggao Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruyi Dingchuan Pill (RDP)
Study: 11004346
Drug: Salivary estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary estriol (E3) test at or above 2.1 ng/mL
Study: 11004346
Drug: Salivary E3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary E3 test at or above 1.4 ng/mL
Study: 8988071
Drug: Ephedrine plus
Normalized name: EPHEDRINE HYDROCHLORIDE 12.5 mg / GUAIFENESIN 200 mg ORAL TABLET [Red Label Ephedrine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine plus caffeine (20 mg ephedrine plus 200 mg caffeine three times a day)
Study: 1730189
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g every 8 hr
Study: 1730189
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g every 12 hr
Study: 6143505
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg sublingually, followed by 10 mg every 6 hours for a total of 24 hours)
Study: 31460669
Drug: Concurrent opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent opioids with benzodiazepines or nonbenzodiazepine sedatives (BZD-S)
Study: 30518044
Drug: NU-AGE diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NU-AGE diet group (dietary intervention for one year including 15 food groups and vitamin D supplement)
Study: 22424012
Drug: Transendocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial injection of autologous aldehyde dehydrogenase-bright (ALDH(br)) cells
Study: 20142410
Drug: One course
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One course of adjuvant CVB chemotherapy for VASC- patients
Study: 20142410
Drug: Two courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two courses of adjuvant CVB chemotherapy for VASC+ patients
Study: 20142410
Drug: Adjuvant CVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CVB chemotherapy (both groups)
Study: 19020146
Drug: Demand-only PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand-only PCEA (5 mL bolus, 15 min lockout interval)
Study: 19020146
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with background infusion (5 mL/h, 5 mL bolus, 12 min lockout interval)
Study: 19020146
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with background infusion (10 mL/h, 5 mL bolus, 10 min lockout interval)
Study: 7493430
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human growth hormone, subcutaneously, daily dose of 0.02-0.05 i.u./kg at bedtime
Study: 31125576
Drug: Sorafenib-pravastatin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib-pravastatin combination (arm A)
Study: 22794223
Drug: SAF as
Normalized name: SAF-GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAF as an adjunct after K3
Study: 20700793
Drug: Topical nipradilol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nipradilol
Study: 19203070
Drug: ACE‐inhibitor quinaprilat
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE‐inhibitor quinaprilat 0.5 mg/h administered intravenously via infusion pump
Study: 19203070
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard inotropic‐vasodilator therapy)
Study: 11861525
Drug: PPARγ agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARγ agonists (chronic treatment for 11 days)
Study: 11861525
Drug: Rosiglitazone (14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (14-day treatment)
Study: 11861525
Drug: Metformin or
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin or PPARα agonist (treatment)
Study: 11861525
Drug: Severe insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Severe insulin resistance patients (dominant-negative PPARγ mutations)
Study: 7488811
Drug: Budesonide (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (inhaled steroid)
Study: 30280515
Drug: 0.1% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% sodium hyaluronate (SH) ophthalmic solution
Study: 30280515
Drug: 0.2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% sodium hyaluronate (SH) ophthalmic solution
Study: 30280515
Drug: 0.3% sodium
Normalized name: Dextrose 5% and 0.3% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% sodium hyaluronate (SH) ophthalmic solution
Study: 30280515
Drug: All sodium
Normalized name: Sodium Chloride 0.9% Intravenous Solution [KENDALL SODIUM CHLORIDE FLUSH SYRINGE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All sodium hyaluronate solutions
Study: 30280515
Drug: All ophthalmic
Normalized name: All Clear Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All ophthalmic solutions